- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01262183
Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus (PANORAMIC)
A Randomised Phase II Study of Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus
For esophageal cancer that can not be removed by surgery, the choice of treatment is a combination of chemotherapy and radiotherapy. We call this combination- (or concurrent) chemoradiotherapy. Chemotherapy is treatment with drugs that kill cancer cells. Both chemotherapy and radiotherapy make the tumour smaller and enhance each other's effect. The goal of treatment with chemotherapy and radiation therapy is to cure the cancer. Unfortunately only a small proportion of patients are cured with this treatment.
Improvements in the outcome of treatment may be expected by using the so-called "targeted" treatments. With esophageal cancer, a protein (the epidermal growth factor receptor (this is a kind of trap), the EGFR), is present in many tumours. This protein causes the tumor to grow. Panitumumab is a drug that blocks the functioning of this receptor (catcher), so that possibly the growth and spread of esophageal cancer is prevented.
The main objective of this trial is to see if survival of patients with inoperable esophageal cancer improves as panitumumab is added to standard treatment with chemoradiotherapy.
It will also investigate whether patients tolerate the addition of panitumumab to the standard treatment. Also, the biological characteristics of the tumor will be examined. In a proportion of patients it will be determined how the enhancement of the cancer is visible on an FDG-PET scan before the start of treatment and how this changes during the treatment. It will be also be evaluated how this treatment affects the survival.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6500 HB
- University Medical Centre Nijmegen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 - 70years
- Histology proven SCC or adenocarcinoma of the oesophagus
- No proven (distant) metastases (ultrasonography, CT or MRI)
- No prior treatment for carcinoma of the oesophagus
- Karnofsky performance status ≥70% (appendix A)
- Irresectable disease as assessed by the multidisciplinary tumour board
- All patients (male and female) must use effective contraception methods according to CPMP/ICH/286/95 if of reproductive potential (e.g. implants, injectables, combined oral contraceptives, IUDs, sexual abstinence or vasectomised partner), for the whole duration of the study and until six months after they received the last treatment dose
- No contraindications for cytotoxic therapy or panitumumab:
- No known hypersensitivity/allergy to any of the compounds used
- Haematology: Neutrophil count ≥ 1.5∙109 /L Thrombocyte count ≥ 100∙109 /L Haemoglobin ≥ 6.2 mmol/L (100 g/L)
- No known HIV infection or other condition of persistent immunodeficiency
- Renal function:
- Creatinine clearance (MDRD) ≥ 60 mL/min
- Hepatic function:
- Total bilirubin ≤ 1.5∙ULN
- AST, ALT, AP ≤ 2.5∙ULN
- Electrolyte balance:
- (albumin corrected) calcium ≤ 2.87 mmol/L (=11.5 mg/dl) but ≥ lower limit of normal (LLN)
- Magnesium ≥ LLN
- History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.
- No known other serious illness or medical condition present at entry in the study including: Unstable cardiac disease despite treatment, congestive heart failure NYHA grade 3 and 4 Clinically significantly abnormal electrocardiogram (ECG) or left ventricular ejection fraction (LVEF) below the institutional ULN
- Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrolment/randomisation
- Significant neurologic or psychiatric disorders
- Active uncontrolled infection Active disseminated intravasal coagulation
- Symptomatic peripheral neuropathy (CTCAE v3.0 term "neuropathy: sensory") ≥ grade 2 Ototoxicity (CTCAE v3.0 any term in "auditory/ear") ≥ grade 2 except if due to trauma or mechanical impairment due to tumour mass
- Other serious underlying medical condition which could impair the ability of the patient to participate in the study No or insufficient oral nutrient intake
- No prior exposure to EGFR pathway targeting agents
- No known drug abuse
- Absence of any psychological, familial, sociological (e.g. severe alcohol addiction expected to hamper protocol compliance) or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- No participation in another interventional clinical trial in the preceding 30 days
- Written informed consent to participate to study must be given according to ICH/GCP, and national/local regulations.
Exclusion Criteria:
- Prior treatment for this tumour
- Prior treatment with radiation therapy in the area of the oesophagus or other site that will interfere with proposed treatment
- Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.
- Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment.
- History of other prior malignancy in past 5 years, other than basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ.
Exclusion criteria for the PET-scan (secondary endpoint)
For the PET-scan the following exclusion criteria are used:
- Severe claustrophobia
- Diabetes mellitus (type I and II)
- Serum glucose level >11 mmol/L
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Concurrent chemoradiation therapy with panitumumab
|
Day -7, day +15 and day +36: panitumumab 9.0 mg/kg i.v.
Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v.
Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
|
ACTIVE_COMPARATOR: Concurrent chemoradiation therapy without panitumumab
|
Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v.
Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1-year overall survival
Time Frame: 1-year
|
To describe the 1-year OS rate after concurrent CRT with or without panitumumab in irresectable carcinoma of the oesophagus.
The control arm is used to validate whether the historical cohort used for comparison is similar to our success-rate.
|
1-year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
toxicity
Time Frame: during treatment and follow up
|
Investigation of the acute and long-term toxicity of both study arms (according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0);
|
during treatment and follow up
|
PFS
Time Frame: between randomisation and date of PD
|
PFS: interval between randomisation date and the date at which disease progression is established being not suspicious for a second cancer (histologically confirmed when in doubt) or date of death from any cause but clearly not related to disease- or treatment (e.g.
accident).
Patients still disease-free after 18 months follow-up or lost to follow-up or death clearly not related to disease or treatment (e.g.
accident)), are censored at the date of the most recent follow-up or at the analysis cut-off date, whichever comes first.
|
between randomisation and date of PD
|
Response Rate
Time Frame: 3 months after treatment
|
Response rate: partial (PR) or complete response (CR) according to RECIST 1.1 at 3 months after treatment
|
3 months after treatment
|
pharmacodynamics of panitumumab
Time Frame: biopsy at baseline (standard) and the biopsy one week after start chemo-radiation therapy
|
pharmacodynamics (PD) of panitumumab (EGFR, K-RAS, B-RAF, downstream signalling pathways ) compared between the biopsy at baseline (standard) and the biopsy one week after start chemo-radiation therapy
|
biopsy at baseline (standard) and the biopsy one week after start chemo-radiation therapy
|
Quantification of baseline FDG uptake (SUV) with PET, and SUV changes
Time Frame: baseline 7 days after the first panitumumab dose or for start chemo-radiation therapy. during treatment with chemoradiation therapy after three weeks.
|
baseline, 7 days after the first panitumumab dose or for start chemo-radiation therapy. during treatment with chemoradiation therapy after three weeks. 2-4 weeks after finishing treatment. 10-12 weeks after finishing treatment |
baseline 7 days after the first panitumumab dose or for start chemo-radiation therapy. during treatment with chemoradiation therapy after three weeks.
|
CTCs and CECs
Time Frame: baseline,after 2 weeks during chemo-radiation therapy and 12 weeks after finishing treatment
|
baseline,after 2 weeks during chemo-radiation therapy and 12 weeks after finishing treatment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Neoplasms, Squamous Cell
- Adenocarcinoma
- Carcinoma, Squamous Cell
- Esophageal Neoplasms
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Panitumumab
Other Study ID Numbers
- UMCNONCO200905
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irresectable Squamous Cell or Adenocarcinoma of the Oesophagus
-
Centre Hospitalier Universitaire DijonTerminatedEpidermoid Carcinoma or | Adenocarcinoma of the Thoracic Oesophagus or | Adenocarcinoma of the Oesogastric Junction (Siewert Type I or II) | Stage cT2 N1-3 M0 or cT3-T4a N0 or N1-3 M0France
-
Laboratorio Elea Phoenix S.A.CompletedSquamous Cell Carcinoma of the Cervix | Adenocarcinoma of the CervixArgentina
-
Royal Marsden NHS Foundation TrustEli Lilly and Company; AstraZeneca; Clovis Oncology, Inc.; MedImmune LLCRecruitingAdenocarcinoma of the Stomach | Adenocarcinoma of the Oesophagus | Adenocarcinoma of the Gastro-oesophageal JunctionUnited Kingdom
-
Jules Bordet InstituteInnate PharmaWithdrawnAdenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the EsophagusBelgium
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage II Gastric Cancer | Stage III Gastric Cancer | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Stomach | Adenocarcinoma of the Esophagus | Stage III Esophageal Cancer | Stage II Esophageal CancerUnited States
-
Tarveda TherapeuticsRecruitingNeoplasms | Carcinoma | Small Cell Lung Carcinoma | Gastric Cancer | Pancreatic Adenocarcinoma | Solid Tumor | Gastric Adenocarcinoma | Small-cell Lung Cancer | Advanced Cancer | Pancreatic Ductal Adenocarcinoma | Adenocarcinoma of the Pancreas | Endometrial Adenocarcinoma | Squamous Cell Carcinoma of the Penis | Gastroesophageal... and other conditionsUnited States
-
Heidelberg UniversityCompletedSinonasal Malignancies | Adenocarcinoma and Squamous Cell Carcinoma of the Paranasal SinusesGermany
-
Vanderbilt-Ingram Cancer CenterBoehringer Ingelheim; National Comprehensive Cancer NetworkWithdrawnSquamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head or Neck | Metastatic Squamous Cell Carcinoma of the Head or Neck
-
Mitchell MachtayNot yet recruitingSquamous Cell Carcinoma of the Oral Cavity or Oropharynx
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Esophagus | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Stage III Esophageal CancerUnited States
Clinical Trials on CRT + Panitumumab
-
Medtronic Cardiac Rhythm and Heart FailureMedtronicCompleted
-
University of Alabama at BirminghamRecruiting
-
Children's Hospital of PhiladelphiaThe Hilda & Preston Davis FoundationCompleted
-
Inova Health Care ServicesMedtronicRecruitingLeft Bundle-Branch Block | Heart Failure (HF) | Left Ventricular Ejection FractionUnited States
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonNot yet recruiting
-
University Hospital OlomoucNot yet recruiting
-
CMC Ambroise ParéWithdrawnCompare Two Programming Modalities for CRT Devices in Heart Failure Patients With an Indication for Cardiac Resynchronization TherapyMonaco, France
-
Medtronic Cardiac Rhythm and Heart FailureCompletedHeart Diseases | Atrioventricular BlockUnited States, Canada
-
Medtronic Cardiac Rhythm and Heart FailureTerminatedCongestive Heart Failure | Systolic Heart Failure | Left Bundle Branch BlockUnited States, Sweden, India, Russian Federation, United Kingdom
-
Montreal Heart InstituteCanadian Institutes of Health Research (CIHR); Abbott Medical DevicesTerminated